

Award winning research

Cartrophen research in humans with knee joint osteoarthritis wins the annual Charles R Ream Award for Excellence in 2005.

Further information and research on our website www.cartrophenvet.com.au

Evidence based veterinary medicine

Evidence based medicine is now in focus. Veterinarians recognise the need to base drug use on research carried out on the product they use and not to accept similar molecules as being the same eg sodium pentosan polysulfate (PPS). Decisions based on scientific research and clinical use will benefit your patient.

"There is nothing more expensive than using a medication that does not work".

Cartrophen Vet wins with research

Biopharm Australia is a research driven internationally recognised company. With over 400 references published on the PPS found in Cartrophen Vet and extensive collaboration with numerous research institutes and Universities worldwide, Biopharm Australia is a world leader on PPS and disease modifying osteoarthritis drug (DMOAD) research.

Latest achievements

Biopharm Australia is collaborating with a Japanese company to develop Cartrophen for humans* in Japan.

Cartrophen Vet will be available in 2007 for veterinary use in Japan.

Two publications have recently been submitted to join the list of 400 plus scientific references on the PPS contained in Cartrophen Vet, a list that includes horse toxicology and kinetic (calcium derivative) research findings.

NEW equine studies to start in Sweden and Australia.

VISIT us at this years AEVA conference.



www.arthritis.au.com

* Safety dose in man has yet to be established by regulatory authorities.